Abstract: Provided is a preparation method of a free fatty acid particle dispersion solution, the preparation method including: a) dissolving fatty acid in a solvent to prepare a fatty acid solution; and b) injecting the fatty acid solution in a non-solvent having miscibility with the solvent to prepare a free fatty acid particle dispersion solution.

Abstract: A method of making one or more alcohols with a single hydroxy group, such as methanol and ethanol, the method comprising contacting a polyol and water with a basic catalyst. The polyol may be glycerol, for example. The catalyst may be magnesium oxide.

Abstract: Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included.

Abstract: The present invention relates to compounds of Formula I and Formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of Formula I and Formula II; and formulated to treat an underlying etiology by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.

Abstract: Provided are a white-emitting monomolecular compound using excited-state intramolecular proton transfer (ESIPT) characteristics, and an organic electroluminescence device and a laser device comprising same. The white-emitting monomolecular compound according to the present invention is prepared by covalently bonding at least two types of molecules which produce different colors and have excited-state intramolecular proton transfer (ESIPT) characteristics. The white-emitting monomolecular compound according to the present invention achieves white luminescence irrespective of the concentration thereof and of the state of the materials thereof, and therefore can be used in a variety of fields including an organic electroluminescence device and a laser device.

Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein groups L, M, X and Y are as defined herein.

Abstract: The invention relates to the pharmaceutical industry and to medicine, specifically to novel hydrated amino-acid derivatives of fullerene C60 of general formula C60(H)3{NH(CH2)nCOOH}3.xH2O, where C60-fullerene, n=5, 6, 7, x=8-10, and also to a method for producing said derivatives, and to the production of pharmaceutical compositions on the basis thereof. Hydrated N-fullerene amino acids are formed in the interaction of fullerene with 15 times the molar excess of anhydrous potassium salts of amino acids in a medium of organic aromatic solvent with slow addition to the resultant suspension of an interphase catalyst and with mixing and heating to a temperature not exceeding 60° C. until the solution is completely decolorized and a solid residue formed, after which the latter is separated out, and then 0.8 M of aqueous solutions of potassium salts of fullerene amino-acid derivatives is treated with a solution of organic or mineral acids, followed by centrifugation, rinsing and drying of the residue.

Abstract: A process for the production of ethylene glycol comprising: (i) supplying ethylene and oxygen and an organic chloride moderator to an EO reactor, thereby producing a reactor product stream; (ii) supplying the reactor product stream to an EO absorber, thereby producing a fat absorbent stream; (iii) supplying the fat absorbent stream to an EO stripper, thereby producing a concentrated ethylene oxide stream and a lean absorbent stream; (iv) recirculating the lean absorbent stream to the EO absorber; and (v) supplying the ethylene oxide stream and/or the ethylene carbonate stream to hydrolysis reactors with an alkali metal salt hydrolysis catalyst to form an ethylene glycol stream; wherein the process additionally comprises: (vi) removing a glycol bleed stream from the ethylene oxide stripper; and (vii) adding a base to the ethylene oxide stripper such that the pH in the bottom section of the stripper is maintained from 9.5 to 12.0.

Abstract: The present invention relates to pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula III: wherein the variables are as defined herein.

Abstract: The present disclosure describes anti-wear compounds that improve the pack stability of a lubricant composition and are resistant to in situ degradation while maintaining effective anti-wear performance.

Abstract: Trisphenols of general formula (1), which are useful as starting materials for polymer, are industrially easily produced by a method using as a starting material 4-aralkylphenol derivatives expressed by general formula (2): wherein X represents a hydrogen atom or leaving group that can be substituted with a hydrogen atom.

Abstract: The present invention relates to the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. Also provided are methods for the treatment and/or prevention of one or more metabolic disorders, for example, obesity or diabetes, utilizing fatostatin A and/or a derivative and/or analog thereof and/or the A-B-C tripartite compounds.

Abstract: Estrogen-Related Receptor (ERR) modulating compounds and methods for synthesis of said compounds are described.

Abstract: The present invention relates to metal amides of the formula (I), to a process for preparation thereof and to the use thereof as bases for aromatics, heteroaromatics, alkenes, alkynes and other organic compounds having activated C—H bonds.

Abstract: The present invention relates to novel diphenylethyne derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Abstract: A surface-modified polymer is described, comprising a polymeric material and a self-assembling monolayer covalently bound thereto. The monolayer comprises monoethylene glycolated-OH (MEG-OH); 2-(3-trichlorosilyl-propyloxy)-ethyl-trifluoroacetate (7-OEG or MEG-TFA); 2,2,2-trifluoroethyl-13-trichlorosilyl-tridecanoate (TTTA); OEGylated TTTA (OEG-TTTA); S-(2-(2-(2-(3-trichlorosilyl-propyloxy)-ethoxy)-ethoxy)-ethyl)-benzenethiosulfonate (OEG-TUBTS); or a combination thereof. Methods are described for forming a surface-modified polymer by surface activation, such as with plasma. By utilizing the surface-modified polymer to make medical equipment or devices for contacting biological fluids, a reduction in surface fouling and thrombus formation can result. Advantageously, polymeric equipment or components so modified may have a reduction in unwanted chemical interactions leading to fouling or clotting.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

Abstract: Provided are a white-emitting monomolecular compound using excited-state intramolecular proton transfer (ESIPT) characteristics, and an organic electroluminescence device and a laser device comprising same. The white-emitting monomolecular compound according to the present invention is prepared by covalently bonding at least two types of molecules which produce different colors and have excited-state intramolecular proton transfer (ESIPT) characteristics. The white-emitting monomolecular compound according to the present invention achieves white luminescence irrespective of the concentration thereof and of the state of the materials thereof, and therefore can be used in a variety of fields including an organic electroluminescence device and a laser device.

Abstract: The invention relates to peptides of general formula (I): that can reduce or remove bags formed under the eyes, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or dermopharmaceutically acceptable salts thereof, wherein X is cystenyl, seryl, threonyl or aminobutyryl; R1 is H or alkyl, aryl, aralkyl or acyl group; and R2 is amino, hydroxy or thiol, all of them substituted or non-substituted with aliphatic or cyclic groups. The invention also relates to a method of obtaining, cosmetic or dermopharmaceutical compositions containing them and their use for treating skin, preferably for reducing or removing bags formed under the eyes.